Table 5.6d
Immunosuppression Use for Maintenance by Regimen
Prior to Discharge, 1996 to 2005
Recipients with Kidney Transplants

	Transplant Year									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Functioning Graft at Discharge	10,889	11,241	11,999	12,274	13,103	13,812	14,323	14,689	15,535	16,005
With Immunosuppression Info	10,687	11,195	11,931	12,089	12,886	13,788	14,260	14,614	15,402	15,523
--- + MMF/MPA	0.0%	0.1%	0.3%	0.1%	0.1%	0.1%	0.2%	0.4%	0.4%	0.5%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	0.2%	0.4%	0.6%	0.3%
--- + MMF/MPA + Steroids	2.0%	2.4%	2.6%	2.8%	1.6%	1.4%	1.2%	1.6%	1.7%	2.0%
--- + OtherAntimet	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + OtherAntimet + Steroids	3.6%	0.5%	0.3%	0.3%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.3%	0.1%	0.2%	0.4%	0.2%
--- + Siro/Evero + Steroids	0.0%	0.0%	0.1%	0.2%	0.5%	0.5%	0.4%	0.6%	0.4%	0.2%
--- + Steroids	5.3%	1.5%	2.1%	1.9%	1.2%	1.0%	0.8%	1.3%	1.7%	1.4%
CyA	0.3%	0.4%	0.3%	0.2%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%
CyA + MMF/MPA	0.6%	0.5%	0.7%	0.6%	0.9%	0.9%	0.7%	1.6%	1.7%	1.3%
CyA + MMF/MPA + OtherAntimet	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	0.2%	0.2%	0.0%	0.0%
CyA + MMF/MPA + Steroids	39.2%	50.0%	48.2%	46.7%	37.1%	27.6%	22.9%	18.3%	14.2%	10.0%
CyA + OtherAntimet	0.4%	0.3%	0.2%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Siro/Evero	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	23.1%	14.5%	8.8%	5.7%	3.6%	2.2%	0.8%	0.4%	0.2%	0.1%
CyA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.4%	0.9%	1.2%	1.3%
CyA + Siro/Evero + Steroids	0.7%	1.5%	2.9%	1.9%	5.0%	3.6%	2.9%	2.2%	1.4%	1.2%
CyA + Steroids	8.6%	6.3%	5.4%	5.0%	3.1%	1.7%	1.2%	1.4%	1.4%	0.4%
Tac	0.1%	0.1%	0.1%	0.2%	0.5%	1.1%	2.0%	1.0%	1.3%	1.4%
Tac + MMF/MPA	0.1%	0.3%	0.6%	0.8%	1.1%	1.7%	2.9%	6.6%	13.7%	19.2%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%
Tac + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	0.4%	1.2%	0.7%	0.5%
Tac + MMF/MPA + Steroids	6.0%	12.5%	20.2%	26.4%	31.4%	38.6%	46.1%	46.8%	46.4%	50.6%
Tac + OtherAntimet	0.0%	0.0%	0.1%	0.0%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%
Tac + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + OtherAntimet + Steroids	2.1%	1.9%	1.9%	1.4%	1.1%	1.3%	1.1%	0.9%	0.5%	0.2%
Tac + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.4%	1.2%	1.3%	1.7%	1.9%	1.1%
Tac + Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.2%	4.4%	6.4%	4.8%	4.7%	3.4%	2.4%
Tac + Steroids	3.3%	2.9%	2.9%	3.2%	3.5%	3.9%	3.3%	2.2%	2.5%	2.3%
Other Regimen	4.2%	4.1%	2.3%	2.2%	3.7%	5.5%	6.0%	4.9%	3.8%	3.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Percentages in each column sum to 100 percent.
---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.
MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.
"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.